Therefore, we then used two different type I receptor (ALK4/ALK5) small molecule inhibitors, EW-7197 or SB-505124 to directly assess the contribution of Activin receptors in the activation of Smad signaling in breast cancer cells. Here, ACVR1B is linked to breast carcinoma.